Compare Nu Holdings Ltd (NU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Nu Holdings Ltd trades at $15 (market cap $74.05B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Nu Holdings Ltd is far larger — about 39.8× Recursion Pharmaceuticals Inc's market cap, and Nu Holdings Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NU | RXRX | |
|---|---|---|
Market Cap | $74.05B | $1.86B |
Sector | Financials | Health |
52-Week High | $18.76 | $6.79 |
52-Week Low | $11.60 | $2.84 |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings stock trades at $15.33, down slightly by 0.26% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.20. The company reported strong Q2 2026 results, including a 39% revenue growth and record net income exceeding $1 billion, driven by expanding customer base and AI integration. Cash flow from operations reached $3.5 billion in 2025, supporting robust financial health.
Outlook remains positive with growth opportunities in Mexico and AI-driven efficiencies, but risks include credit quality concerns and competitive pressures. Analysts are predominantly bullish, with 57% recommending buy, though investors should monitor debt levels and macroeconomic factors affecting fintech sectors.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
